Back HIV/AIDS

HIV / AIDS

CROI 2013: Growing Number of HIV+ New Yorkers Achieve Viral Load Suppression [VIDEO]

Expanded testing, earlier treatment, and better engagement in care has led to more people with HIV in New York City achieving and maintaining undetectable viral load, according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last month in Atlanta.

alt

CROI 2013: Antiretroviral Therapy Intensification plus IL-7 Does Not Reduce HIV Reservoir

 An intensive antiretroviral regimen containing raltegravir (Isentress) and maraviroc (Selzentry) plus the immune-modulator interleukin 7 (IL-7) was unable to decrease the amount of residual HIV in resting CD4 T-cells, investigators with the ERAMUNE-01 trial reported at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

CROI 2013: Transmitted Antiretroviral Drug Resistance Holds Steady at 16% [VIDEO]

Approximately 1 in 6 analyzed HIV sequences showed evidence of antiretroviral drug resistance, with NNRTIs being particularly vulnerable, according to a CDC analysis presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

French Cohort of HIV+ People Treated Early Appear to Control Virus

A group of French HIV patients who started antiretroviral therapy (ART) during the earliest stage of infection appear to be controlling the virus despite prolonged treatment interruption, according to a recent report in PLoS Pathogens. While the findings do not represent a cure, they may offer insight to help certain people with HIV achieve a "functional cure," or periods off treatment without disease progression.

alt

CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction [VIDEO]

Long-awaited results from the VOICE trial of post-exposure prophylaxis (PrEP) for women in Africa, presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, was not able to show that daily oral tenofovir plus emtricitabine (the drugs in Truvada) could lower the risk of HIV acquisition.

alt

CROI 2013: Researchers Look at Neurological Complications among People with HIV

Data from a small, yet well-designed trial to evaluate whether particular antiretroviral therapy (ART) regimens penetrate the central nervous system (CNS) and enhance neurocognitive performance were among several interesting findings regarding neurological complications among people with HIV presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta. Another study looked at similarities between Alzheimer's disease and neurocognitive impairment in people with HIV.

alt

CROI 2013: Maraviroc Does Not Prevent Immune Reconstitution Syndrome [VIDEO]

The CCR5 co-receptor blocker maraviroc (Selzentry) did not reduce the risk of developing immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy (ART), according to study findings presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt